Use in chronic kidney disease; Use immediately
Bisphosphonates can offer substantial clinical benefit in conditions in which an imbalance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption
Side effects for all the bisphosphonates (alendronate, ibandronate, risedronate and zoledronic acid) may include bone, joint or muscle pain
16% of reviewers reported a positive effect, while 81% reported a negative
Ibandronate (IBN) (ibandronate sodium hydrate) is available for intravenous administration for the treatment of osteoporosis
Both risedronate and alendronate are approved to prevent hip fractures in women with osteoporosis [36, 37]
Bisphosphonate use results in a rapid
Since their general availability and wide scale use, however, there have been occasional publications reporting clinically apparent acute liver injury due to the more commonly used bisphosphonates
2008]
ibandronate 한달에 한번 투약도 위장관계 부작용의 빈도가 줄어들진 않았고 일주일에 한번 복용하는 약물간 부작용을 직접 비교한 결과는 없다
001 risedronate (Actonel), according to Procter & Gamble Pharmaceuti-cals, Cincinnati (M
Sustained fracture prevention was seen in a zoledronate trial lasting 6 years,24 and some studies suggest that anti-fracture efficacy persists for 3–5 years Yanik et al performed a comparison study of the renal safety of risedronate, alendronate, and raloxifene, Risedronate and ibandronate, which have a lower incidence of nephrotoxicity, have been studied in CKD patients with CrCl <30 mg/mL
Most of the BRONJ cases reported in literature show a strong correlation with dental pathologies, dental extractions, and/or oral surgical
A similar range of cutaneous adverse reactions to alendronate have been reported: rash in 3—4% of cases and pruritus in 2% [Vidal, 2009; FDA, 2002]
With respect to bone mineral density (BMD), alendronate, ibandronate, risedronate and zoledronic acid have been shown to increase BMD by 5-7% and 1
Depending on the condition being treated and the dosage used, alendronate may be taken once daily or once weekly
Intravenous ibandronate injection in postmenopausal women with osteoporosis showed comparable safety levels to that of alendronate, with only small changes in the serum creatinine , but
[alendronate, risedronate, ibandronate, pamidronate, zoledronate] act on bone metabolism by binding and blocking the enzyme farnesyl diphosphate synthase (FPPS) in this HMG-CoA reductase pathway